Related Experiment Video
Updated: Jul 15, 2026
Neuronavigation and Laparoscopy Guided Ventriculoperitoneal Shunt Insertion for the Treatment of Hydrocephalus
Published on: October 14, 2022
Pediatric gravitational shunts: initial results from a prospective study
Regina Eymann1, Wolf-Ingo Steudel, Michael Kiefer
1Department of Neurosurgery, Saarland University Medical School, Saarland, Germany. ReginaEymann@web.de
Insights
The Miethke Paedi-GAV shunt shows promise as a safe and effective option for pediatric hydrocephalus. Preliminary results suggest it is suitable for further randomized trials comparing pediatric shunts.
Area of Science:
- Neurosurgery
- Pediatric hydrocephalus management
Background:
- Hydrocephalus is a common neurological condition in children requiring cerebrospinal fluid (CSF) diversion.
- Existing shunts have varying efficacy and complication rates, necessitating ongoing research into improved devices.
- The Miethke Paedi-GAV is a novel gravitational shunt designed for pediatric use.
Purpose of the Study:
- To prospectively evaluate the efficacy and safety of the Miethke Paedi-GAV shunt in pediatric patients.
- To determine if the Miethke Paedi-GAV warrants inclusion in randomized controlled trials comparing pediatric shunts.
Main Methods:
- A prospective study involving 55 children (0-6 years) undergoing primary shunt implantation with the Miethke Paedi-GAV.
- Follow-up duration ranged from 12 to 77 months (mean 47 months).
- Primary endpoint was the first shunt failure requiring revision; complications and drainage issues were also assessed.
Main Results:
- 1- and 2-year shunt survival rates were 75% and 68%, respectively.
- The complication rate was 33%, with specific issues including underdrainage (1.8%) and overdrainage (3.6%).
- No slitlike ventricles were observed on imaging, indicating appropriate CSF drainage.
Conclusions:
- The Miethke Paedi-GAV demonstrates safety and effectiveness in the pediatric population.
- These findings support the inclusion of the Miethke Paedi-GAV in comparative randomized trials.
- The shunt represents a potentially valuable addition to the management of pediatric hydrocephalus.
Object:
The authors' goal in this paper was to evaluate prospectively the efficacy and safety of a new pediatric gravitational shunt to determine whether it warrants inclusion in a randomized, controlled trial with other shunts.
Methods:
A total of 55 children between the ages of 0 and 6 years (median age 0.5 years, average age 4+/-6 years) underwent primary shunt implantation; all received the Miethke Paedi-GAV. The follow-up period ranged between 12 and 77 months (mean 47+/-21 months). The primary end point of the study was the first shunt failure necessitating revision. The 1- and 2-year shunt survival rates were 75 and 68%, respectively. The average failure-free shunt survival duration was 1423 +/- 641 days. Based on imaging findings, no slitlike ventricles occurred. The complication rate was 33%, and the median time to shunt failure was 45 days. Underdrainage occurred in one child (1.8%) and overdrainage in two children (3.6%).
Conclusions:
These preliminary results prove the Miethke Paedi-GAV to be a safe and effective pediatric shunt worthy of inclusion in a randomized comparison with other shunts in the pediatric population.